Skip to content

Acetaminophen and Chlorpheniramine Maleate Premedication in Chronically Transfused Patients: A Prospective, Randomized Controlled Trial

Acetaminophen and Chlorpheniramine Maleate Premedication in Chronically Transfused Patients: A Prospective, Randomized Controlled Trial

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
TCTR
Registry ID
TCTR20221011002
Enrollment
94
Registered
2022-10-11
Start date
2021-12-02
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Efficacy of chlorpheniramine maleate and acetaminophen premedication in prevent febrile nonhemolytic transfusion reaction in chronically transfused patient. chronically transfused patient premedication febrile nonhemolytic transfusion reaction

Interventions

acetaminophen (500) 1 tab po in patient with body weight less than 67 kg, or 2 tab po in patient with body weight equal or more than 67 kg and chlorpheniramine maleate 10mg IV before transfusion of fi
Active Comparator Drug,Placebo Comparator Drug
Premedications,Placebo

Sponsors

Supanat Janyangam
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Patient receiving red cell transfusion at least 2 unit from the same cause in the last 3 months 2. Hemoglobin level before transfusion is below 8 gm/dL 3. At least 18 years of age

Exclusion criteria

Exclusion criteria: 1. Patient receiving red cell transfusion from acute blood loss 2. Patient receiving red cell transfusion related to trauma 3. Patient receiving red cell transfusion related to surgery 4. History of febrile illness following transfusion in the last 3 months 5. History of allergic reaction following transfusion in the last 3 months 6. Acetaminophen allergy 7. Chlorpheniramine maleate allergy 8. Febrile illness within 24 hours prior to transfusion 9. Allergic reaction within 24 hours prior to transfusion 10. Patient receiving acetaminophen, chlorpheniramine maleate, other antihistamine, or corticosteroid equivalent to 5mg of prednisolone within 48 hours prior to transfusion

Design outcomes

Primary

MeasureTime frame
Incidence of febrile nonhemolytic transfusion reaction and allergic transfusion reaction after received acetaminophen and chlorpheniramine maleate premedication before LPRC transfusion within 24 hours after transfusion vital signs and clinical during transfusion, self-recorded body temperature and clinical after transfusion

Secondary

MeasureTime frame
Incidence of febrile nonhemolytic transfusion reaction after received acetaminophen and chlorpheniramine maleate premedication before LPRC transfusion within 24 hours after transfusion vital signs and clinical during transfusion, self-recorded body temperature and clinical after transfusion,Incidence of allergic transfusion reaction after received acetaminophen and chlorpheniramine maleate premedication before LPRC transfusion within 24 hours after transfusion vital signs and clinical during transfusion, self-recorded body temperature and clinical after transfusion,difference of incidence of other transfusion reaction between arm receiving acetaminophen and chlorpheniramine maleate premedication, and placebo before LPRC transfusion within 24 hours after transfusion vital signs and clinical during transfusion, self-recorded body temperature and clinical after transfusion,Incidence of complications related to transfusion in this study within 24 hours after transfusion vital signs and clinical during transfusion, self-recorded body temperature and clinical after transfusion,adverse reaction of acetaminophen and chlorpheniramine maleate use in this study within 24 hours after transfusion vital signs and clinical during transfusion, self-recorded body temperature and clinical after transfusion,Incidence of febrile nonhemolytic transfusion reaction, allergic transfusion reaction and other transfusion reactions after LPRC transfusion in each disease in this study within 24 hours after transfusion vital signs and clinical during transfusion, self-recorded body temperature and clinical after transfusion

Countries

Thailand

Contacts

Public ContactSupanat Janyangam

Faculty of Medicine, Chulalongkorn University

s.janyangam@gmail.com022564000

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026